Literature DB >> 3030577

Immunobiology of complete molar pregnancy and gestational trophoblastic tumor.

R S Berkowitz, S A Umpierre, S Taylor-Emery, D P Goldstein, D J Anderson.   

Abstract

The unique curability of gestational trophoblastic tumors may in part be attributable to a host immunologic response. The occurrence of rapidly progressive and fatal choriocarcinoma may be favored by histocompatibility between patients and their partners. However, histocompatibility is not a prerequisite for the development and persistence of gestational choriocarcinoma. The expression of HLA by choriocarcinoma cells in culture is enhanced following incubation with gamma-interferon and this may be of both biologic and clinical significance. Complete molar pregnancy is a complete allograft because all molar chromosomes are of paternal origin. Patients with complete mole are sensitized to paternal HLA antigen which is expressed in molar tissue. Other polymorphic antigen systems including trophoblast-leukocyte common antigens and placental-type alkaline phosphatase are also expressed in molar tissue. We have studied the immunopathology of the molar implantation site to investigate possible humoral and cellular immune responses. The relationships among normal placenta, complete mole and choriocarcinoma are not clearly understood. The pattern of expression of oncofetal antigens in these three gestational tissues may be used to assess trophoblastic differentiation. In studies to date, molar trophoblast has the same pattern of expression of oncofetal antigens as normal placental trophoblast. We will review recent advances in our understanding of the immunobiology of gestational trophoblastic disease and suggest new directions for further research.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3030577     DOI: 10.1007/BF00046426

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  84 in total

1.  Cellular reaction to choriocarcinoma.

Authors:  C W Elston
Journal:  J Pathol       Date:  1969-02       Impact factor: 7.996

2.  HLA antigens in husband-wife pairs with trophoblastic tumor.

Authors:  K Yamashita; M Ishikawa; T Shimizu; M Kuroda
Journal:  Gynecol Oncol       Date:  1981-08       Impact factor: 5.482

3.  Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells.

Authors:  M Fellous; U Nir; D Wallach; G Merlin; M Rubinstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

4.  Immunosuppressive properties of murine trophoblast.

Authors:  P Van Vlasselaer; M Vandeputte
Journal:  Cell Immunol       Date:  1984-02       Impact factor: 4.868

5.  Gestational trophoblastic neoplasms. Clinical principles of diagnosis and management.

Authors:  D P Goldstein; R S Berkowitz
Journal:  Major Probl Obstet Gynecol       Date:  1982

6.  Inhibition of [3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside.

Authors:  F Sinigaglia; K W Talmadge
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

7.  Purification of human B cell growth factor.

Authors:  S R Mehta; D Conrad; R Sandler; J Morgan; R Montagna; A L Maizel
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

8.  Differential expression of trophoblast-specific membrane antigens by normal and abnormal human placentae and by neoplasms of trophoblastic and non-trophoblastic origin.

Authors:  Y W Loke; A Whyte; S P Davies
Journal:  Int J Cancer       Date:  1980-04-15       Impact factor: 7.396

9.  Immunologic studies in patients with trophoblastic neoplasia.

Authors:  Y Tomoda; M Fuma; N Saiki; N Ishizuka; T Akaza
Journal:  Am J Obstet Gynecol       Date:  1976-11-15       Impact factor: 8.661

10.  Induction of idiotype-specific suppressor T cells with antigen/antibody complexes.

Authors:  M J Caulfield; K J Luce; M R Proffitt; J Cerny
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.